Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Patricia S. Braly"'
Autor:
Mohammad Azab, Ursula A. Matulonis, H Hirte, Bristi Basu, Susana Banerjee, John Nemunaitis, Harold N. Keer, Benjamin Schwartz, Deborah K. Armstrong, Patricia S. Braly, Merry Jennifer Markham, Rebecca Kristeleit, Lynda D. Roman, Diane Provencher, Daniela Matei, Sue Naim, Geoff Hall, Aram Oganesian, Simone Jueliger, Sarah P. Blagden, Michael J. Birrer, Sharad A. Ghamande, Kenneth P. Nephew, Angeles Alvarez Secord, Amit M. Oza, Yong Hao, William P. McGuire, Gini F. Fleming
Publikováno v:
Clin Cancer Res
Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0132937e4799a70c839d4097d50cabd8
https://doi.org/10.1158/1078-0432.ccr-19-1638
https://doi.org/10.1158/1078-0432.ccr-19-1638
Autor:
Francessco Plotti, Giovanni Scambia, Gabriella Ferrandina, Christopher F. Nicodemus, Corrado Terranova, Vanda Salutari, Caterina Ricci, Patricia S. Braly, Paolo Scollo, Eliel Bayever, Francesco Raspagliesi, Michael W. Method, Robert W. Holloway, Pierluigi Benedetti Panici, Molly Brewer, Madi Madiyalakan, Roberto Angioli, Domenica Lorusso
Background This randomized phase II study tested the hypothesis that schedule dependent chemo-immunotherapy with oregovomab improves progression free survival (PFS) and overall survival (OS) in optimally resected, Stage III/IV ovarian cancer. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a86eff605a7505518e2bd692f2006d
http://hdl.handle.net/10807/145298
http://hdl.handle.net/10807/145298
Autor:
Patricia S. Braly, Jyoti Chauhan, Christopher A Breed, Dennis Yi-Shin Kuo, Robert W. Holloway, Devansu Tewari, Sarah Gill, John O. Schorge, Sunil Gupta, Michael A. Gold, Susan C. Modesitt, Angeles Alvarez Secord, Cathy Reddick
Publikováno v:
Journal of Clinical Oncology. 39:TPS5606-TPS5606
TPS5606 Background: Oregovomab binds tumor-associated CA125 rendering the target antigen CA125 more immunogenic or “neoantigen-like” through altered and enhanced antigen processing and presentation to specific T cells. This phenomenon is hypothes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06cf8b4db96ca6baa29e493bfb809ded
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5606
https://doi.org/10.1200/jco.2021.39.15_suppl.tps5606
Autor:
Michael W. Method, Christina Chu, Lesley Mary Smith, Christopher Schoonmaker, Theresa L. Whiteside, Robert Edwards, Christopher F. Nicodemus, Yvonne Collins, Patricia S. Braly, Alan N. Gordon, William McGuire
Publikováno v:
Journal of Immunotherapy. 32:54-65
Oregovomab is a monoclonal antibody that recognizes CA125 and forms circulating immune complexes that can elicit immunity against both tumor antigen and tumor. This study was designed to assess combining this immunotherapy at 2 dosing schedules with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::625ec2953a0b0a5eea83942f55d343f2
https://doi.org/10.1097/cji.0b013e31818b3dad
https://doi.org/10.1097/cji.0b013e31818b3dad
Autor:
Kathleen Dunlap, Patricia Kissinger, Ann M. Gaffga, Rebecca A. Clark, Patricia S. Braly, Michael E. Hagensee, Anil K. Chaturvedi, Joeli A. Brinkman, Jeanne Dumestre
Publikováno v:
Journal of General Virology. 85:1237-1241
The prevalence of human papillomavirus type 16 E6 variant lineages was characterized in a cross-sectional study of 24 human immunodeficiency virus type 1 (HIV)-positive and 33 HIV-negative women in New Orleans. The European prototype was the predomin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad88225d315e04c403c576ac7de7c19
https://doi.org/10.1099/vir.0.19694-0
https://doi.org/10.1099/vir.0.19694-0
Autor:
Rebecca A. Clark, Ann M. Gaffga, Jeanne Dumestre, Kathleen Dunlap, Patricia Kissinger, Ansley F. Hammons, Kristina M. Mire, Tracy E. Beckel, Anil K. Chaturvedi, Patricia S. Braly, Michael E. Hagensee
Publikováno v:
Journal of Medical Virology. 75:105-113
Prevalence of 27 human papillomavirus (HPV) genotypes was assessed in 1,331 women in three clinical settings: Family planning clinic (low-risk HIV-, n = 202, 21.3% HPV+), colposcopy clinic (high-risk HIV-, n = 854, 34.3% HPV+), and HIV outpatient cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5e40cc4a3f6d1e3389ec282edaeb5be
https://doi.org/10.1002/jmv.20244
https://doi.org/10.1002/jmv.20244
Autor:
Sharon P. Wilczynski, Mace L. Rothenberg, David S. Alberts, Scott Wadler, Patricia S. Braly, P.Y. Liu, Caroline Jiang, Edward V. Hannigan, Maurie Markman, Gavin Stuart
Publikováno v:
Journal of Clinical Oncology. 21:1313-1319
Purpose: The median survival time for women with optimally debulked adenocarcinoma of the ovary treated with intravenous (IV) chemotherapy is 41 to 52 months, and the 2-year survival rate is 65% to 70%. Recent studies evaluating intraperitoneal (IP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f5b6127ad8c49a4671549a784af0ba
https://doi.org/10.1200/jco.2003.07.031
https://doi.org/10.1200/jco.2003.07.031
Autor:
Bradley J. Monk, I Malinowska, Amit M. Oza, Ashley Haggerty, Patricia S. Braly, L.A. Rojas, Bhavana Pothuri, Diane Provencher, J. Barter, Ying Fei Li, Christof Vulsteke, David M. O'Malley, Ignace Vergote, Whitney Graybill, A. Gonzalez Martin, Mansoor Raza Mirza
Publikováno v:
Annals of Oncology. 28:v351
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6e319dd76aa9044985eb8916af27a14
https://doi.org/10.1093/annonc/mdx372.057
https://doi.org/10.1093/annonc/mdx372.057
Autor:
Francesco Plotti, Roberto Angioli, Domenica Lorusso, Madi Madiyalakan, Gabriella Ferrandina, Michael W. Method, Sergio Pecorelli, Giovanni Scambia, Vanda Salutari, Caterina Ricci, Christopher F. Nicodemus, Patricia S. Braly, Paolo Scollo, Francesco Raspagliesi, Molly Brewer, Corrado Terranova, Robert W. Holloway, Pierluigi Benedetti Panici
Publikováno v:
Journal of Clinical Oncology. 35:5536-5536
5536 Background: In a phase II study of vaccination schedule in front-line combinatorial treatment of EOC (Braly JIT 2009), simultaneous day infusion dramatically enhanced the magnitude of induced immunity relative to a one week delayed schedule & ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb208eac47b161ed49f268e81a33629
https://doi.org/10.1200/jco.2017.35.15_suppl.5536
https://doi.org/10.1200/jco.2017.35.15_suppl.5536
Autor:
Martin Gore, Richard T. Penson, Kathleen M. Moore, Rebecca R. Hozak, Hoa Nguyen, Susana Banerjee, Paul Haluska, Gini F. Fleming, Yihuan Xu, Adarsh Joshi, Jonathan D. Schwartz, Diane C. Bodurka, Ursula A. Matulonis, William P. McGuire, Veronica L. Schimp, Patricia S. Braly
Vascular endothelial growth factor (VEGF) receptor-mediated signaling contributes to ovarian cancer pathogenesis. Elevated VEGF expression is associated with poor clinical outcomes. We investigated ramucirumab, a fully human anti-VEGFR-2 antibody, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f4955f3fde6e994be8161935ef6ad98
https://europepmc.org/articles/PMC5166425/
https://europepmc.org/articles/PMC5166425/